Journal of Headache and Pain

Papers
(The median citation count of Journal of Headache and Pain is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study324
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine138
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis110
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache85
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency77
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation71
Debate: Are cluster headache and migraine distinct headache disorders?65
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks60
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study60
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia56
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China48
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine47
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine43
Measuring interictal burden among people affected by migraine: a descriptive survey study42
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results41
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients41
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI38
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury37
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey35
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States34
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study33
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas32
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study32
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting32
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study32
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain31
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study30
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients29
Development and validation of a novel model for characterizing migraine outcomes within real-world data29
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-201928
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study28
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients28
Tracking the evolution of non-headache symptoms through the migraine attack28
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients27
Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study27
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review26
Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients26
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis26
Contribution of tetrodotoxin-resistant persistent Na+ currents to the excitability of C-type dural afferent neurons in rats26
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure26
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study25
Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine25
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation24
Correction: Applying a biopsychosocial model to migraine: rationale and clinical implications24
Effects of a history of headache and migraine treatment on baseline neurocognitive function in young athletes24
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab23
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 rece23
Long COVID headache23
Long term evaluation of a multidisciplinary trigeminal neuralgia service21
The economic and personal burden of cluster headache: a controlled cross-sectional study21
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury21
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience20
Interictal osmophobia is associated with longer migraine disease duration20
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update20
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis20
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database20
0.11269187927246